The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gurevich L.E.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI)

Vasyukova O.A.

Avtsyn Research Institute of Human Morphology of «Petrovsky National Research Centre of Surgery»

Mikhaleva L.M.

A.P. Avtsyn Research Institute of Human Morphology

Bondarenko E.V.

M.F. Vladimirsky Moscow Regional Research Clinical Institute;
Endocrinology Research Centre

Shikina V.E.

M.F. Vladimirsky Moscow Regional Research Clinical Institute

Characteristics of gastric neuroendocrine tumors and the PDX-1 transcription factor expression

Authors:

Gurevich L.E., Vasyukova O.A., Mikhaleva L.M., Bondarenko E.V., Shikina V.E.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2024;86(3): 12‑20

DOI: 10.17116/patol20248603112

Read: 1346 times

Download PDF (RU)
Contact the author
Table of contents

CHARACTERISTICS OF GASTRIC NEUROENDOCRINE TUMORS AND THE PDX-1 TRANSCRIPTION FACTOR EXPRESSION
CHARACTERISTICS OF GASTRIC NEUROENDOCRINE TUMORS AND THE PDX-1 TRANSCRIPTION FACTOR EXPRESSION

To cite this article:

Gurevich LE, Vasyukova OA, Mikhaleva LM, Bondarenko EV, Shikina VE. Characteristics of gastric neuroendocrine tumors and the PDX-1 transcription factor expression. Russian Journal of Archive of Pathology. 2024;86(3):12‑20. (In Russ.)
https://doi.org/10.17116/patol20248603112

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The phenomenon of tumor budding in gastric cancer. Russian Journal of Archive of Pathology. 2025;(2):79-87
Prognostic value of mole­cular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations. Russian Journal of Archive of Pathology. 2025;(3):88-96
Difficult intu­bation risk asse­ssment in bariatric surgery. Russian Journal of Anesthesiology and Reanimatology. 2025;(1):62-68
Analysis of dyna­mics and fore­cast of morbidity of diseases of the urogenital system in the child popu­lation living in the Repu­blic of Sakha (Yakutia). Russian Journal of Preventive Medi­cine. 2025;(3):60-66
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
Prognostic significance of NT-proBNP and sST2 in patients with chro­nic heart failure and redu­ced ejection fraction after previous deco­mpensation. Russian Cardiology Bulletin. 2025;(1):49-56
Diagnostic and prognostic pote­ntial of modern biomarkers in community-acquired pneumonia in children. Russian Journal of Preventive Medi­cine. 2025;(4):130-135
Pathogenetic aspe­cts of autoantibody formation to central nervous system stru­ctures in patients with ence­phalitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):53-58
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Hema­tological indi­cators of the systemic inflammatory response in the prognosis of lumi­nal HER2-negative breast cancer patients unde­rgoing surgery followed by adju­vant therapy. P.A. Herzen Journal of Onco­logy. 2025;(3):31-38
Abstract:

OBJECTIVE

To study the features of gastric neuroendocrine tumors (NETs) and the diagnostic and prognostic significance of PDX-1 expression in them.

MATERIAL AND METHODS

207 NETs identified in 56 men and 115 women (59 had multiple NETs), and 94 cases of gastric cancer (comparison group) were studied morphologically and immunohistochemically.

RESULTS

In more than half of the cases (54.93%), NETs were localized in the body of the stomach; the cardiac and antral parts of the stomach accounted for 8.64% and 11.73%, respectively. NETs of the cardiac region predominated in men, and of the body and antrum — in women. NETs of the cardiac region predominated in men, and of the body and antrum — in women. The vast majority of NETs were highly differentiated (89.20%), of which Grade 1, 2 and 3 were 55.41%, 40.76% and 3.82%, respectively. Neuroendocrine carcinomas (NEC) accounted for 10.80% of all NET cases. NECs were more often localized in the cardiac part of the stomach and accounted for 35.71% of all NETs in the cardiac part. The share of NEC among all NETs of the antrum was 15.79%, of the body of the stomach — only 3.37%. Metastases were found in 17.90% of NETs. Expression of PDX-1 was detected in 44.73% of NETs, 70% of NECs and 74.50% of gastric cancers.

CONCLUSION

PDX-1 is involved in the mechanisms of precancerous and cancerous lesions of the stomach and its overexpression is detected in the majority of the most malignant NETs and gastric cancers.

Keywords:

gastric neuroendocrine tumors
location
type
Grade
transcription factor PDX-1 expression
prognosis

Authors:

Gurevich L.E.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI)

Vasyukova O.A.

Avtsyn Research Institute of Human Morphology of «Petrovsky National Research Centre of Surgery»

Mikhaleva L.M.

A.P. Avtsyn Research Institute of Human Morphology

Bondarenko E.V.

M.F. Vladimirsky Moscow Regional Research Clinical Institute;
Endocrinology Research Centre

Shikina V.E.

M.F. Vladimirsky Moscow Regional Research Clinical Institute

Received:

24.10.2023

Accepted:

28.02.2024

Close metadata

References:

  1. Panzuto F, Campana D, Massironi S, Faggiano A, Rinzivillo M, Lamberti G, Sciola V, Lahner E, Manuzzi L, Colao A, et al. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: a multicentre retrospective study. Dig Liver Dis. 2019;51(10):1456-1460. https://doi.org/10.1016/j.dld.2019.04.016
  2. Sackstein PE, O’Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45(4):249-258.  https://doi.org/10.1053/j.seminoncol.2018.07.001
  3. WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Digestive system tumours. 5th ed. Vol. 1. France, Lyon: International Agency for Research on Cancer; 2019. https://tumourclassification.iarc.who.int
  4. La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014;67(11):938-948.  https://doi.org/10.1136/jclinpath-2014-202515
  5. Algashaamy K, Garcia-Buitrago M. Multifocal G1-G2 gastric neuroendocrine tumors: differentiating between Type I, II and III, a clinicopathologic review. World J Clin Cases. 2019;7(17):2413-2419. https://doi.org/10.12998/wjcc.v7.i17.2413
  6. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735-752.  https://doi.org/10.1097/MPA.0b013e3181ebb168
  7. Massironi S, Sciola V, Spampatti MP, Peracchi M, Conte D. Gastric carcinoids: between underestimation and overtreatment. World J Gastroenterol. 2009;15(18):2177-2183. https://doi.org/10.3748/wjg.15.2177
  8. Exarchou K, Stephens NA, Moore AR, Howes NR, Pritchard DM. New developments in gastric neuroendocrine neoplasms. Curr Oncol Rep. 2022;24(1):77-88.  https://doi.org/10.1007/s11912-021-01175-y
  9. La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, Capella C, Bordi C, Solcia E. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42(10):1373-1384. https://doi.org/10.1016/j.humpath.2011.01.018
  10. Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A, Buzzoni R, et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morthological differentiation and proliferation identify different prognostic categories. Neuroendocrinology. 2017;104(1):85-93.  https://doi.org/10.1159/000445165
  11. Ma J, Chen M, Wang J, Xia HH, Zhu S, Liang Y, Gu Q, Qiao L, Dai Y, Zou B, et al. Pancreatic duodenal homeobox-1 (PDX1) functions as a tumor suppressor in gastric cancer. Carcinogenesis. 2008;29(7):1327-1333. https://doi.org/10.1093/carcin/bgn112
  12. Buettner M, Dimmler A, Magener A, Brabletz T, Stolte M, Kirchner T, Faller G. Gastric PDX-1 expression in pancreatic metaplasia and endocrine cell hyperplasia in atrophic corpus gastritis. Mod Pathol. 2004;17(1):56-61.  https://doi.org/10.1038/modpathol.3800015
  13. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342. https://doi.org/10.1001/jamaoncol.2017.0589
  14. Calvete O, Reyes J, Zuñiga S, Paumard-Hernández B, Fernández V, Bujanda L, Rodriguez-Pinilla MS, Palacios J, Heine-Suñer D, Banka S, et al. Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. Hum Mol Genet. 2015;24(10):2914-2922. https://doi.org/10.1093/hmg/ddv054
  15. Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res. 2010;162(1):22-25.  https://doi.org/10.1016/j.jss.2010.01.005
  16. Felder S, Jann H, Arsenic R, Denecke T, Prasad V, Knappe-Drzikova B, Maasberg S, Wiedenmann B, Pavel M, Pascher A, et al. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocr Relat Cancer. 2019;26(9):751-763.  https://doi.org/10.1530/ERC-18-0582
  17. Lawrence B, Kidd M, Svejda B, Modlin I. A clinical perspective on gastric neuroendocrine neoplasia. Curr Gastroenterol Rep. 2011;13(1):101-109.  https://doi.org/10.1007/s11894-010-0158-4
  18. Vanoli A, La Rosa S, Miceli E, Klersy C, Maragliano R, Capuano F, Persichella A, Martino M, Inzani F, Luinetti O, et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology. 2018;107(2):114-126.  https://doi.org/10.1159/000489902
  19. Han D, Li YL, Zhou ZW, Yin F, Chen J, Liu F, Shi YF, Wang W, Zhang Y, Yu XJ, et al. Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms. World J Gastroenterol. 2021;27(21):2895-2909. https://doi.org/10.3748/wjg.v27.i21.2895
  20. Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol. 2017;23(3):516-524.  https://doi.org/10.3748/wjg.v23.i3.516
  21. Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, Katai H, Tsuda H, Kushima R. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol. 2013;37(7):949-959.  https://doi.org/10.1097/PAS.0b013e31828ff59d
  22. Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I. Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol. 2006;30(8):945-953.  https://doi.org/10.1097/00000478-200608000-00003
  23. Matsui K, Jin XM, Kitagawa M, Miwa A. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants. Arch Pathol Lab Med. 1998; 122(11):1010-1017.
  24. Leys CM, Nomura S, Rudzinski E, Kaminishi M, Montgomery E, Washington MK, Goldenring JR. Expression of Pdx-1 in human gastric metaplasia and gastric adenocarcinoma. Hum Pathol. 2006;37(9):1162-1168. https://doi.org/10.1016/j.humpath.2006.04.011
  25. Buettner M, Dimmler A, Magener A, Brabletz T, Stolte M, Kirchner T, Faller G. Gastric PDX-1 expression in pancreatic metaplasia and endocrine cell hyperplasia in atrophic corpus gastritis. Mod Pathol. 2004;17(1):56-61.  https://doi.org/10.1038/modpathol.3800015
  26. Sakai H, Eishi Y, Li XL, Akiyama Y, Miyake S, Takizawa T, Konishi N, Tatematsu M, Koike M, Yuasa Y. PDX1 homeobox protein expression in pseudopyloric glands and gastric carcinomas Gut. 2004;53(3):323-330.  https://doi.org/10.1136/gut.2003.026609
  27. Oz Puyan F, Can N, Ozyilmaz F, Usta U, Sut N, Tastekin E, Altaner S. The relationship among PDX1, CDX2, and mucin profiles in gastric carcinomas; correlations with clinicopathologic parameters. J Cancer Res Clin Oncol. 2011;137(12):1749-1762. https://doi.org/10.1007/s00432-011-1044-7
  28. Gurevich LE, Proshchina AE, Voronkova IA, Ashevskaya VE, Korosteleva PA, Dolzhanskii OV. Differential diagnostic value of the expression of the transcription factor PDX-1 in neuroendocrine and non-neuroendocrine tumors of the pancreas and other organs. Arkhiv Patologii. 2019;81(5):11-21. (In Russ.). https://doi.org/10.17116/patol20198105111
  29. Yu J, Liu SH, Sanchez R, Nemunaitis J, Rozengurt E, Brunicardi FC. PDX1 associated therapy in translational medicine. Ann Transl Med. 2016;4(11):214.  https://doi.org/10.21037/atm.2016.03.51
  30. Zhou G, Sinnett-Smith J, Liu SH, Yu J, Wu J, Sanchez R, Pandol SJ, Abrol R, Nemunaitis J, Rozengurt E, et al. Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin. Front Physiol. 2014;5:226.  https://doi.org/10.3389/fphys.2014.00226
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.